Back to results
UnknownPhase 3

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

NCT00430001

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Department of Oncology, Rigshospitalet

Copenhagen, Denmark

Contact

Michael Andersson, MD D Med Sci

+45 35458105michael.andersson@dadlnet.dk
View on ClinicalTrials.gov
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer — TrialFind